Trial Design

An expert team is using innovative trial methodologies to develop rare disease trial design, addressing key issues inherent in rare disease trials.

Research lead

Prof Simon Gates

Simon Gates is Professor of Biostatistics and Clinical Trials at the Cancer Research UK Clinical Trials Unit (CRCTU). He is a Deputy Director of CRCTU and is involved in design, supervision, analysis and reporting of clinical trials in paediatric cancer and a variety of other fields. His main research interests are in improving the efficiency of clinical trials so that they can provide better and more clinically useful answers, more quickly. He specialises in the use of adaptive multi-arm trial designs, and for the use of Bayesian statistical methods in clinical research

University lead

Prof James Wason – Newcastle University

Prof Wason is a statistician with interests in methods for improving the efficiency of clinical trials through better design and analysis approaches, focusing on improving trials for immune-mediated inflammatory diseases.

Prof Mike Clarke – Queens University Belfast

Prof Clarke has worked on randomised trials, systematic reviews and studies of research methodology for nearly 30 years. He has a strong interest in increasing research capacity and in improving access to research.

Area Overview

Developing effective treatments for people living with rare diseases (PLWRD) requires innovative and efficient clinical trial methodologies. This research area will establish a multi-disciplinary expert team to design and conduct practice-changing national and international trials, ensuring they are patient-centric, methodologically robust, and aligned with health technology assessment (HTA) standards

By integrating advanced trial designs, we will address the challenges of small patient populations and heterogeneous disease presentations, ensuring rare disease trials are both scientifically rigorous and accessible. 

This initiative will support trial setup and delivery, working in collaboration with researchers, clinicians, and regulatory bodies to streamline the design, approval, and execution of rare disease trials. A key focus will be developing trial documentation and governance frameworks, ensuring seamless trial implementation alongside patient and public involvement (PPIE) strategies to promote diverse and representative recruitment. As the LifeArc Translational Challenge for Rare Disease progresses, this research area will expand its scope to support a broader range of trials across the initiative. 

By pioneering efficient, patient-focused trial methodologies, we aim to accelerate the availability of new treatments for rare diseases. These trial designs will use innovate methodologies around Bayesian statistical methods, synthetic control experience and casual inference to leverage complex trial designs for the greatest result.  

Interested in working with the team?

We are always looking for talented researchers, clinicians, and industry partners to join our efforts in accelerating rare disease trials. Whether you’re interested in research collaboration, clinical trial design, or patient engagement, we’d love to hear from you.